本次续约适应症为： 用于治疗由对本品敏感的金黄色葡萄球菌(包括甲氧西林敏感及耐药菌 株)、化脓性链球菌或无乳链球菌引起的复杂性皮肤和软组织感染。 管线持续推进，拓展更多治疗可能 2025年12月7日，根据国家医保局、人力资源社会保障部发布《国家基本医疗保险、工伤 保险和生育保险药品目录(2025年)》(以下简称"新版药品目录")，新版药品目录将于2026 年1月1日起正式实施。上海盟科药业股份有限公司(股票代码：688373)自主研发的噁唑烷 酮类1类新药康替唑胺片(优喜泰®)成功以"0降幅"续约新版药品目录，协议期为2026年1月 1日-2027年12月31日。成功续约的康替唑胺片继续沿用当前价格和支付范围，仍然享受 国谈产品身份，期待未来2年的协议期内康替唑胺片持续惠及更多复杂性皮肤及软组织感染 患者。 从上市到医保，优喜泰®一路"加速跑" 2021年6月：优喜泰®在中国获批上市； 2022年1月：首次纳入国家医保目录，惠及更多 患者； 2023年12月：首次续约成功，协议期两年； 2025年12月：成功续约，维持原价， 进入第三个协议期。 - 注射用MRX-4已于2025年5月提交中国NDA并获受理，拟 ...

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with Nanjing Pengbo Biotechnology Co., Ltd. to jointly develop innovative antibody-drug conjugates (ADCs) leveraging their respective platforms [2][3] Group 1: Company Overview - Mengke Pharmaceutical focuses on the design and development of small molecule new drugs, aiming to discover, develop, and commercialize innovative drugs that meet unmet clinical needs [2] - The company has successfully developed a new STOPIN (Soft Topoisomerase Inhibitor) platform to address dose-limiting toxicities caused by toxins in next-generation ADC development [2] Group 2: Research and Development Progress - Mengke Pharmaceutical presented research progress on a new ADC product based on the STOPIN toxin platform at the 2024 European Society for Medical Oncology (ESMO), showing excellent anti-tumor efficacy and lower hematological toxicity in animal trials [2] Group 3: Strategic Partnership - The partnership with Pengbo Biotechnology aims to maximize the applicability and competitiveness of the STOPIN platform technology, facilitating the development of competitive ADC drugs globally [3] - Pengbo Biotechnology provides comprehensive CDMO services to accelerate new drug development for biotech and pharmaceutical companies, covering clinical trials to commercial production [3]